Trevena, Inc. Presents Phase 1 Clinical Data for TRV027, a ß-arrestin Biased AT1R Ligand, at the 2012 Heart Failure Society of America Meeting
9/7/2012 10:29:57 AM
KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc., the leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, today announced that it is presenting a poster featuring Phase 1 clinical data on TRV027 at the 16th Annual Heart Failure Society of America Meeting being held in Seattle, WA, September 9th-12th. Trevena is developing TRV027 for the treatment of acute decompensated heart failure. TRV027 is the most advanced drug in Trevena’s pipeline, and currently the subject of a Phase 2a dose finding study in stable chronic heart failure patients. The Phase 1 first-time-in-human clinical study of the drug was successfully completed in 2010.
comments powered by